Scleral cross-linking device
By designing a scleral cross-linking device with a reflective structure and a non-zero angle light port, the problem that traditional devices cannot achieve uniform irradiation is solved, and the treatment effect is improved.
Patent Information
- Application Number
- CN202421104287.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-20
- Publication Date
- 2025-04-08
- Estimated Expiration
- 2034-05-20
AI Technical Summary
Traditional scleral cross-linking devices cannot guarantee uniform irradiation to the scleral action area, resulting in poor treatment effect.
A scleral cross-linking device is designed, including a treatment cavity, light channel, drug application channel and recovery channel. Through a reflective structure and a non-zero-angle light port design, uniform light and cross-linking treatment of the sclera are achieved.
Through the reflective structure and non-zero angle light port design, uniform light illumination on the sclera is achieved, improving the effect of cross-linking treatment.
Smart Images
Figure CN222723225U_ABST
Abstract
Description
Technical Field
[0001] The utility model relates to the technical field of medical equipment, in particular to a sclera cross-linking device. Background Art
[0002] According to the classification of refractive components, myopia can be divided into refractive myopia and axial myopia. Axial myopia is caused by the continuous growth of the eye axis. When the eye axis grows to a certain extent, the various layers of tissue in the eyeball wall (retina, choroid, sclera) will become thinner, and then various pathological changes will easily occur, leading to a series of complications, including retinal detachment, retinoschisis, myopic maculopathy and choroidal atrophy, which can cause blindness in severe cases. The matrix layer is the main structure of the sclera and is composed of collagen fibers. Through the cross-linking effect of ultraviolet rays and the photosensitizer riboflavin, the cross-linked collagen fibers can be made stronger, thereby increasing the biomechanical strength of the sclera. Therefore, scleral cross-linking technology can increase the hardness of the posterior pole of the sclera, thereby controlling the growth of the eye axis and preventing myopia.
[0003] However, most conventional sclera cross-linking devices use optical fibers as the irradiation light source. Even if multiple optical fibers are used as a dot matrix light source, it still cannot ensure uniform irradiation of the sclera action area. Utility Model Content
[0004] The embodiment of the utility model provides a sclera cross-linking device, which can perform uniform light irradiation and cross-linking treatment on the sclera.
[0005] According to an embodiment of the utility model, a scleral cross-linking device is provided, comprising:
[0006] a body having opposite first and second ends;
[0007] a treatment structure located at the second end of the body and comprising a treatment cavity, the treatment cavity being closed at a distal end by an inner bottom surface and having a treatment opening aligned with the sclera of the eyeball at a proximal end, and comprising an inner side wall extending from the distal end to the proximal end;
[0008] an illumination structure, comprising: an illumination channel extending from the first end of the body to an illumination port on the inner side wall, and a light source disposed at the first end, wherein the orientation of the illumination port forms a non-zero angle relative to the orientation of the treatment opening;
[0009] a drug application channel extending from the first end of the main body to a drug application port on the inner side wall;
[0010] a recovery channel extending from the first end of the body to a recovery port on the inner side wall;
[0011] Wherein, the inner bottom surface of the treatment cavity includes a reflective portion, and at least a portion of the inner side wall includes a reflective portion.
[0012] Preferably, in any embodiment,
[0013] At least a portion of the inner bottom surface of the treatment cavity has a concave shape.
[0014] Preferably, in any embodiment,
[0015] At least a portion of the inner bottom surface of the treatment cavity has a convex shape.
[0016] Preferably, in any embodiment,
[0017] The illumination channel is a single illumination channel.
[0018] Preferably, in any embodiment,
[0019] The inner wall of the illumination channel at least partially has a total reflection layer.
[0020] Preferably, in any embodiment,
[0021] The light source includes a light emitting diode (LED) light source.
[0022] Preferably, in any embodiment,
[0023] The light source is detachably mounted to a light source interface at the first end of the body.
[0024] Preferably, in any embodiment,
[0025] The treatment cavity has a shape that expands toward the treatment opening.
[0026] Preferably, in any embodiment,
[0027] The drug dispensing port has a circular, oval or elongated shape.
[0028] Preferably, in any embodiment, it further comprises:
[0029] An inflatable sealing ring disposed at the treatment opening;
[0030] A sealing passage extends from the first end of the body into the sealing ring.
[0031] The sclera cross-linking device provided by the embodiment of the utility model can perform uniform illumination and cross-linking treatment on the sclera. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] In order to more clearly illustrate the embodiments of the utility model or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be discussed below. Obviously, the technical solutions described in conjunction with the drawings are only some embodiments of the utility model. For ordinary technicians in this field, other embodiments and their drawings can be obtained based on the embodiments shown in these drawings without paying creative work.
[0033] Figure 1 It is a schematic structural diagram of a sclera cross-linking device according to an embodiment of the utility model.
[0034] Figure 2 is a top view of a sclera cross-linking device according to an embodiment of the utility model. DETAILED DESCRIPTION
[0035] The following will be combined with the accompanying drawings to clearly and completely describe the technical solutions of various embodiments of the utility model. Obviously, the described embodiments are only part of the embodiments of the utility model, not all of them. Based on the embodiments described in the utility model, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the utility model.
[0036] The embodiment of the utility model provides a sclera cross-linking device, which can perform uniform light irradiation and cross-linking treatment on the sclera.
[0037] According to an embodiment of the utility model, a scleral cross-linking device is provided, comprising:
[0038] a body having opposite first and second ends;
[0039] a treatment structure located at the second end of the body and comprising a treatment cavity, the treatment cavity being closed at a distal end by an inner bottom surface and having a treatment opening aligned with the sclera of the eyeball at a proximal end, and comprising an inner side wall extending from the distal end to the proximal end;
[0040] an illumination structure, comprising: an illumination channel extending from the first end of the body to an illumination port on the inner side wall, and a light source disposed at the first end, wherein the orientation of the illumination port forms a non-zero angle relative to the orientation of the treatment opening;
[0041] a drug application channel extending from the first end of the main body to a drug application port on the inner side wall;
[0042] a recovery channel extending from the first end of the body to a recovery port on the inner side wall;
[0043] Wherein, the inner bottom surface of the treatment cavity includes a reflective portion, and at least a portion of the inner side wall includes a reflective portion.
[0044] In this way, the incident light provided by the light source enters the treatment cavity through the illumination channel (which extends from the first end of the main body to the illumination port on the inner side wall of the treatment cavity), and is reflected (e.g., multiple reflections) by the reflective structure in the treatment cavity (e.g., the inner bottom surface and the reflective part on the inner side wall of the treatment cavity), and then irradiates the sclera of the eyeball through the treatment opening. Since the illumination port of the illumination channel is not consistent with the treatment opening (i.e., they are at a non-zero angle to each other), the incident light entering the treatment cavity from the illumination port will not directly pass through the treatment opening to irradiate the sclera of the eyeball, but will be reflected by the reflective structure in the treatment cavity (e.g., the reflective part on the inner bottom surface and the inner side wall of the treatment cavity) before passing through the treatment opening at a suitable angle to irradiate the sclera of the eyeball. In such a light reflection process, the light that finally passes through the treatment opening can have a more uniform and soft irradiation effect, which is beneficial for sclera cross-linking treatment.
[0045] Among them, the drugs required for scleral cross-linking treatment (such as riboflavin solution, saline or oxygen, etc.) can be provided from the drug application port to the treatment cavity through the drug application channel. When necessary, these drugs (such as excess or used drugs) can be discharged and recovered from the recovery port through the recovery channel.
[0046] In addition, these channels have other uses or functions. For example, when it is necessary to inject riboflavin solution or saline through the medication channel, the recovery channel needs to be connected to the outside world at the first end to balance the internal and external pressures of the treatment cavity. For another example, when the riboflavin absorption reaches a predetermined time, the excess riboflavin solution can be extracted through the recovery channel connected to the recovery pump. At this time, the medication channel needs to be connected to the outside world at the first end to balance the internal and external pressures of the treatment cavity. For another example, similar to the above situation, when using saline for flushing, the used saline can be extracted through the recovery channel. At this time, the medication channel needs to be connected to the outside world at the first end to balance the internal and external pressures of the treatment cavity. In addition, during the illumination stage, it is necessary to continuously apply oxygen to the treatment cavity through the medication channel to ensure the activity of the sclera. At this time, it is necessary to discharge oxygen through the recovery channel to balance the internal and external pressures of the treatment cavity.
[0047] It can be seen that the sclera can be uniformly illuminated and cross-linked by the sclera cross-linking device provided in the embodiment of the utility model.
[0048] It should be noted here that the first end and the second end of the main body refer to specific areas or parts on the main body, and are not limited to endpoints in a narrow sense.
[0049] It should be noted here that although the illumination channel, drug administration channel, and recovery channel all extend from the first end to the second end of the main body, these channels are independent channels passing through the main body and extend from different positions of the first end of the main body into the treatment cavity.
[0050] Optionally, in any embodiment, the non-zero angle formed between the direction of the illumination port and the direction of the treatment opening is 10 to 170 degrees, for example, 60 to 120 degrees, preferably 80 to 100 degrees.
[0051] Optionally, in any embodiment, the non-zero angle formed between the direction of the illumination port and the direction of the treatment opening is an acute angle, an obtuse angle, or a right angle.
[0052] Optionally, in any embodiment, the reflective portion on the inner bottom surface or the inner side wall of the treatment cavity is at least a portion of the inner surface of the inner bottom surface or the inner side wall.
[0053] Optionally, in any embodiment, the reflective portion on the inner bottom surface or inner side wall of the treatment cavity includes a reflective coating applied on the inner bottom surface or inner side wall.
[0054] Preferably, in any embodiment, at least a portion of the inner bottom surface of the treatment cavity has a concave shape. In this way, the concave portion of the inner bottom surface can appropriately converge the incident light entering the treatment cavity through the light irradiation port, which is particularly useful when the light intensity is insufficient or small, and can ensure that the light finally irradiated onto the sclera of the eyeball through the treatment opening has sufficient light intensity.
[0055] Preferably, in any embodiment, the inner bottom surface of the treatment cavity is concave as a whole. Such an overall concave structure is easier to manufacture and process.
[0056] Preferably, in any embodiment, at least a portion of the inner bottom surface of the treatment cavity has a convex shape. In this way, the convex portion of the inner bottom surface can appropriately diverge the incident light entering the treatment cavity through the illumination port, which is particularly useful when the illumination intensity is too high, and can ensure that the light finally irradiated onto the sclera of the eyeball through the treatment opening has a uniform and soft illumination effect.
[0057] Optionally, in any embodiment, at least a portion of the inner bottom surface of the treatment cavity has micro-protrusions. Similarly, the micro-protrusions can appropriately diverge the light to improve the uniformity and softness of the illumination. It should be understood that the micro-protrusions can be arranged on the concave area of the inner bottom surface to increase local scattering, or can be arranged on the convex area of the inner bottom surface to further increase the divergence of the light, both for the purpose of improving the uniformity and softness of the illumination.
[0058] Optionally, in any embodiment, the micro-protrusions are located on the inner bottom surface which is generally concave.
[0059] Optionally, in any embodiment, the micro-protrusions are arranged on a portion of the overall concave inner bottom surface close to the second end of the main body (i.e., farther from the first end of the main body). In this way, after the incident light enters the treatment cavity through the illumination channel extending from the first end of the main body to the illumination port (towards the second end of the main body), more of the incident light is directly irradiated onto the portion of the inner bottom surface closer to the second end of the main body (rather than the portion of the inner bottom surface farther from the second end of the main body), thereby achieving a better dispersion (scattering) effect on the light, which is more conducive to achieving uniform and soft illumination.
[0060] Optionally, in any embodiment, the micro-protrusion includes a plurality of protrusions.
[0061] Optionally, in any embodiment, the micro-protrusion includes a plurality of ridges.
[0062] Optionally, in any embodiment, the micro-protrusions include continuous or discontinuous protrusion rings.
[0063] Optionally, in any embodiment, the micro-protrusion comprises a plurality of concentric protrusion rings.
[0064] Optionally, in any embodiment, the inner wall of the treatment cavity has a convex structure, so that before the light is emitted from the treatment opening of the treatment cavity, it can be diverged by the convex structure on the inner wall of the treatment cavity, so as to achieve uniform and soft lighting.
[0065] Optionally, in any embodiment, the raised structure includes a plurality of ridges, for example, a plurality of ridges parallel to the axis of the treatment cavity.
[0066] Optionally, in any embodiment, the protruding structure includes a plurality of continuous or discontinuous protruding rings, for example, a plurality of protruding rings coaxial with the treatment cavity.
[0067] Optionally, in any embodiment, the illumination channel includes: a plurality of sub-illumination channels branching toward the treatment cavity, and the plurality of sub-illumination channels extend to the plurality of illumination ports, respectively. In this way, through the plurality of sub-illumination channels branching from the first end of the main body toward the treatment cavity, the incident light from the light source at the first end can enter the treatment cavity in a dispersed manner from the plurality of corresponding illumination ports via the plurality of sub-illumination channels, respectively. On the one hand, this can be conducive to achieving uniform and soft illumination, and on the other hand, the incident light can be guided into the treatment cavity from a single light source according to a predetermined design (for example, through a plurality of specially arranged sub-illumination channels branching from the main channel). The light source is only arranged at the entrance of the illumination channel at the first end of the main body, thereby avoiding the risk of the optical fiber light source being damaged by accidental contact when entering the main body or the treatment cavity.
[0068] Preferably, in any embodiment, the illumination channel is a single illumination channel. Thus, since the orientation of the illumination port of the illumination channel extending to the treatment cavity is different from the orientation of the treatment opening of the treatment cavity (i.e., the two form a non-zero angle, especially a right angle or an obtuse angle, such as 90 to 120 degrees), the incident light entering the treatment cavity from the illumination port cannot directly pass through the treatment opening to illuminate the sclera area, but first illuminates the inner bottom surface or inner side surface of the treatment cavity facing the illumination port, and can be reflected and dispersed in the treatment cavity to form uniform and soft illumination provided to the sclera area for cross-linking treatment. The illumination channel adopts such a single-channel design, and uniform and soft cross-linking illumination can be achieved by cooperating with the reflective structure inside the treatment cavity. The structure is simple but the effect is good.
[0069] Preferably, in any embodiment, the inner wall of the light irradiation channel at least partially has a total reflection layer. In this way, the incident light from the light source can enter the treatment cavity through the light irradiation channel in a low-loss or loss-free manner.
[0070] Optionally, in any embodiment, the inner wall of the sub-illumination channel at least partially has a total reflection layer. In this way, the incident light from the light source can enter the treatment cavity through each sub-illumination channel in a low-loss or loss-free manner.
[0071] Preferably, in any embodiment, the light source comprises a light emitting diode (LED) light source.
[0072] Optionally, in any embodiment, the light source comprises an optical fiber.
[0073] Preferably, in any embodiment, the light source is detachably mounted to the light source interface at the first end of the main body, so that the light source can be easily repaired or replaced.
[0074] Optionally, in any embodiment, the light source is installed to the light source interface by plugging.
[0075] Optionally, in any embodiment, the light source is mounted to the light source interface by means of a threaded connection.
[0076] Optionally, in any embodiment, the treatment cavity has a cylindrical shape. In this way, the inner side wall of the treatment cavity may have a cylindrical concave shape, which is conducive to converging light to improve light utilization.
[0077] Preferably, in any embodiment, the treatment cavity has a shape that expands toward the treatment opening. In this way, the inner side wall of the treatment cavity may have a concave shape similar to a cone, which is conducive to converging light to improve light utilization.
[0078] Optionally, in any embodiment, the recovery port is lower than the drug dispensing port during the recovery operation, so as to facilitate the discharge of the medicine in the treatment cavity (especially the medicine that sinks to the bottom of the treatment cavity due to gravity) from the treatment cavity.
[0079] Optionally, in any embodiment, the recovery port is located at the lowest point of the inner side wall during the recovery operation, so as to facilitate the discharge of the medicine in the treatment cavity (especially the medicine that sinks to the bottom of the treatment cavity due to gravity) from the treatment cavity.
[0080] Preferably, in any embodiment, the drug dispensing port has a circular, oval or elongated shape.
[0081] Optionally, in any embodiment, the drug dispensing port has a long strip shape, which is conducive to effectively dispersing the drug entering the treatment cavity.
[0082] Preferably, in any embodiment, the recovery port has a circular, elliptical or elongated shape.
[0083] Optionally, in any embodiment, the recovery port has a long strip shape, which can be beneficial for efficiently discharging the medicine in the treatment cavity.
[0084] Optionally, in any embodiment, the recovery channel comprises: a plurality of sub-recovery channels branching toward the treatment cavity, and the plurality of sub-recovery channels extend to a plurality of the recovery ports, respectively, which can facilitate the discharge of the medicine in the treatment cavity.
[0085] Optionally, in any embodiment, a recovery pump is detachably connected to a recovery interface of the recovery channel at the first end of the main body.
[0086] Optionally, in any embodiment, the recovery pump is connected to the recovery port via a three-way valve. In this way, a suitable valve passage can be selected as needed to discharge different types of medicaments from the treatment cavity to a suitable destination for recovery, thereby avoiding possible contamination of the channel or passage by different medicaments.
[0087] Optionally, in any embodiment, the drug administration system is detachably connected to the drug administration interface of the drug administration channel located at the first end of the main body.
[0088] Optionally, in any embodiment, the drug dispensing system is connected to the drug dispensing interface via a three-way valve. In this way, a suitable valve passage can be selected as needed to provide different types of medicaments into the treatment cavity, thereby avoiding possible contamination of the channel or passage by different medicaments.
[0089] Preferably, in any embodiment, it further comprises:
[0090] An inflatable sealing ring disposed at the treatment opening;
[0091] A sealing passage extends from the first end of the body into the sealing ring.
[0092] In this way, the sealing ring can be inflated and deflated through the sealing channel to achieve expansion and contraction, so as to facilitate the insertion and removal of the scleral cross-linking device. In addition, the sealing ring can limit the area that needs to be cross-linked, which can prevent problems such as liquid leakage and light leakage during the scleral cross-linking process, and can effectively prevent the riboflavin solution from contacting the non-cross-linked area, so as to achieve a better cross-linking treatment effect and reduce the risk of eyeball injury.
[0093] Optionally, in any embodiment, the sealing passage is a separate passage passing through the body, extending from the first end of the body to within the sealing ring.
[0094] Optionally, in any embodiment, the outer surface of the sealing ring facing the sclera has a shape that matches the outer shape of the sclera. Since the sclera cross-linking device is located between the orbital bone and the posterior sclera when in use and the fixing effect is enhanced by the sealing ring, the outer surface shape of the sealing ring is adapted to the outer shape of the sclera, which can effectively ensure the fixing effect when contacting the sclera tissue and reduce the risk of eyeball injury caused by excessive local contact pressure.
[0095] Optionally, in any embodiment, a switch valve is provided on the sealing channel.
[0096] Optionally, in any embodiment, the outer surface of the main body facing the sclera of the eyeball has an outer contour that is adapted to the shape of the sclera of the eyeball as a whole. The human eye is a spherical object with a radius of curvature of approximately 11 mm. Although the implantable sclera cross-linking device can have a flat shape, it is advantageous to have an outer contour that takes into account the natural curvature radius of the eyeball. In this way, when the sclera cross-linking device is embedded in the eyeball tissue and a cross-linking treatment is applied to the sclera area with a treatment opening, the outer surface of the main body facing the sclera area has an outer contour that is adapted to the shape of the sclera as a whole (for example, an equal or approximately equal radius of curvature), which can effectively reduce the risk of eyeball injury due to excessive local contact pressure caused by differences in contact shapes.
[0097] Optionally, in any embodiment, the outer surface of the treatment opening facing the sclera is flush with the outer surface of the main body facing the sclera, and preferably they transition smoothly to each other.
[0098] Optionally, in any embodiment, the outer surface of the sealing ring at the treatment opening facing the sclera is flush with the outer surface of the main body facing the sclera, and preferably they transition smoothly to each other.
[0099] Figure 1It is a schematic structural diagram of a sclera cross-linking device according to an embodiment of the utility model.
[0100] Figure 2 is a top view of a sclera cross-linking device according to an embodiment of the utility model.
[0101] exist Figure 1 , 2 In the illustrated embodiment, a scleral cross-linking device can be seen, comprising:
[0102] The main body 100 has opposite first ends ( Figure 1 Right end shown) and second end ( Figure 1 Left end shown);
[0103] A treatment structure located at the second end of the body ( Figure 1 The left end is shown), and includes a treatment cavity 500, which is at the distal end (corresponding to Figure 1 700 away from the reader's direction or Figure 2 The upper end of the middle) is closed by the inner bottom surface 510 and at the proximal end (corresponding to Figure 1 Direction towards the reader or Figure 2 The lower end of the eyeball) has a treatment opening 550 aligned with the sclera of the eyeball, and includes a device extending from the distal end to the proximal end (ie, Figure 1 Extending in a direction perpendicular to the paper surface or Figure 2 The inner wall ( Figure 1 520 is shown as a cylindrical inner side wall);
[0104] The illumination structure comprises: an illumination channel 600, which extends from the first end ( Figure 1 The right end is shown) extending to the illumination port 606 on the inner wall, and the illumination port 606 disposed at the first end ( Figure 1 The light source 601 is shown as the right end, wherein the orientation of the illumination port is at a non-zero angle relative to the orientation of the treatment opening;
[0105] The drug administration channel 700 extends from the first end ( Figure 1 The right end is shown) extending to the drug dispensing port on the inner side wall 520;
[0106] A recovery channel 800 is provided from the first end ( Figure 1 The right end is shown) extending to the recovery port on the inner side wall 520;
[0107] The inner bottom surface 510 of the treatment cavity includes a reflective portion, and at least a portion of the inner side wall 520 includes a reflective portion.
[0108] The sclera cross-linking device provided by the embodiment of the utility model can perform uniform illumination and cross-linking treatment on the sclera.
[0109] It should be noted that, in this article, relational terms such as first and second are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply that there is any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that the process, method, article or equipment including a series of elements not only includes these elements, but also includes other elements not clearly listed, or also includes elements inherent to such process, method, article or equipment. In the absence of more restrictions, the elements limited by the sentence "comprise a ..." do not exclude the existence of other identical factors in the process, method, article or equipment including the elements.
[0110] In the description of multiple elements herein, multiple parallel features connected by "and / or" refer to one or more (or one or more) of these parallel features. For example, "the first element and / or the second element" means: one or more of the first element and the second element, that is, only the first element, or only the second element, or the first element and the second element (both exist at the same time).
[0111] The various embodiments provided in the present invention can be combined with each other as needed. For example, the features of any two, three or more embodiments can be combined with each other to form a new embodiment of the present invention. This is also within the protection scope of the present invention, unless otherwise stated or technically inconsistent and cannot be implemented.
[0112] The above description is only an exemplary embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention shall be included in the scope of protection of the present invention.
Claims
1. A scleral cross-linking device, characterized in that: include: a body having opposite first and second ends; a treatment structure, which is located at the second end of the body and includes a treatment cavity, the treatment cavity being closed at the distal end by an inner bottom surface and having a treatment opening aligned with the sclera of the eyeball at the proximal end, and including an inner side wall extending from the distal end to the proximal end; an illumination structure, comprising: an illumination channel extending from the first end of the body to an illumination port on the inner side wall, and a light source disposed at the first end, wherein the orientation of the illumination port forms a non-zero angle relative to the orientation of the treatment opening; a drug application channel extending from the first end of the main body to a drug application port on the inner side wall; a recovery channel extending from the first end of the body to a recovery port on the inner side wall; Wherein, the inner bottom surface of the treatment cavity includes a reflective portion, and at least a portion of the inner side wall includes a reflective portion.
2. The scleral cross-linking device according to claim 1, characterized in that At least a portion of the inner bottom surface of the treatment cavity has a concave shape.
3. The scleral cross-linking device according to claim 1, characterized in that At least a portion of the inner bottom surface of the treatment cavity has a convex shape.
4. The scleral cross-linking device according to claim 1, characterized in that The illumination channel is a single illumination channel.
5. The scleral cross-linking device according to claim 1, characterized in that The inner wall of the illumination channel at least partially has a total reflection layer.
6. The scleral cross-linking device according to claim 1, characterized in that The light source comprises a light emitting diode (LED) light source.
7. The scleral cross-linking device according to claim 1, characterized in that The light source is detachably mounted to a light source interface at the first end of the body.
8. The scleral cross-linking device according to claim 1, wherein The treatment cavity has a shape that expands toward the treatment opening.
9. The scleral cross-linking device according to claim 1, characterized in that The drug dispensing port has a circular, oval or elongated shape.
10. The scleral cross-linking device according to claim 1, wherein Further including: An inflatable sealing ring disposed at the treatment opening; A sealing passage extends from the first end of the body into the sealing ring.